
1. mol ther. 2003 oct;8(4):559-66.

boosting recombinant vaccinia increases hpv-16 e7-specific cell precursor 
frequencies antitumor effects hpv-16 e7-expressing sindbis virus replicon 
particles.

lin ct(1), hung cf, juang j, l, lin ky, kim tw, wu tc.

author information: 
(1)department pathology, chang gung memorial hospital, taipei, taiwan.

immunotherapy using heterologous prime-boost regimen emerged an
attractive approach generating antigen-specific t-cell-mediated immune
responses tumors infectious diseases. previously linked the
mycobacterium tuberculosis heat-shock protein 70 (hsp70) hpv-16 e7 antigen
creating chimera, e7/hsp70. found nucleic acid vaccines encoding
e7/hsp70 generate strong antitumor immunity. recently, replication-defective 
sindbis virus replicon particle vaccines considered important
vector system vaccine development. study, assessed whether the
combination e7/hsp70 sindbis virus replicon particles (sinrep5-e7/hsp70) and
e7/hsp70 vaccinia (vac-e7/hsp70) enhance e7-specific immune responses
using sequential vaccination. found priming sinrep5-e7/hsp70 and
boosting vac-e7/hsp70 generated highest number e7-specific cd8(+) t
cells best antitumor effect compared combinations. moreover, our
data showed dosage route immunization used study, mice
treated sindbis virus replicon particle prime-vaccinia boost regimen
generated stronger antitumor responses compared mice treated dna
prime-vaccinia boost vaccine regimen. results encourage use the
sindbis virus replicon particle prime-vaccinia boost regimen future clinical
trials.

doi: 10.1016/s1525-0016(03)00238-7 
pmid: 14529828  [indexed medline]

